Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05896813 | CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05893472 | A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. | unknown | Phase 1 / Phase 2 | 45 | ZePing ZhouOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05893693 | Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | unknown | N/A | 12 | Aibin Liang,MD,Ph.D.OTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05892146 | Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction | unknown | N/A | 100 | National Cheng-Kung University HospitalOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | unknown | Phase 3 | 218 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05888701 | "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. | unknown | — | 30 | University of Milano BicoccaOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT03077828 | Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 43 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03226249 | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05855122 | Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | unknown | Phase 4 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05883709 | A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL | unknown | — | 15 | Zhao WeiliOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05264883 | Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | unknown | Phase 3 | 170 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05639673 | Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia | unknown | — | 5,000 | Rigshospitalet, DenmarkOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05874778 | A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission | unknown | Phase 2 | 108 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 25, 2023 | clinicaltrials |
| NCT05140811 | A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 1 / Phase 2 | 126 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05771883 | A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide | unknown | Phase 1 / Phase 2 | 102 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | unknown | Phase 3 | 280 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05860179 | Examination of Trends in Multiple Myeloma Trial Patient Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 23, 2023 | clinicaltrials |
| NCT04923048 | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | unknown | Phase 1 / Phase 2 | 460 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 22, 2023 | clinicaltrials |
| NCT05303155 | The Association of Gut Microbiota With COVID 19 Infection in Children | unknown | — | 40 | Hallym University Kangnam Sacred Heart HospitalOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05471323 | Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML | unknown | Phase 1 | 36 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05858814 | RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT | unknown | Phase 1 / Phase 2 | 72 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT04471064 | A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 60 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies(ANCHOR2) | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT05863845 | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | unknown | N/A | 52 | Ruijin HospitalOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT05271682 | A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma | unknown | Phase 1 | 40 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05859932 | Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 16, 2023 | clinicaltrials |
| NCT05857982 | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05858203 | Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment(AATF/Che-1) | unknown | — | 150 | Regina Elena Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05855460 | Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study | unknown | — | 20 | Cairo UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT03933852 | Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose(Ponderosa) | unknown | — | 100 | University of JenaOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05852028 | A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma | unknown | — | 250 | Ruijin HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | unknown | Phase 1 / Phase 2 | 12 | Emory UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05816746 | Decitabine and Anti-PD-1 in R/R DLBCL | unknown | Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05821738 | Avapritinib in CBF-AML With KIT Mutations | unknown | Phase 2 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT04333108 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | unknown | Phase 3 | 140 | AB ScienceINDUSTRY | 8 | May 6, 2023 | clinicaltrials |
| NCT05252403 | Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL | unknown | Phase 2 | 35 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05840289 | A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma(FRILLY) | unknown | — | 94 | University Hospital, GenevaOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT04356846 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05834751 | the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma | unknown | N/A | 144 | Ou Bai, MD/PHDOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT01685814 | Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance | unknown | Phase 3 | 406 | Wuerzburg University HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05832125 | Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia(ALLTARGETOBS) | unknown | — | 80 | Versailles HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04139252 | A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients(HO902DLBCL) | unknown | — | 250 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04957693 | Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period | unknown | N/A | 40 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05823701 | Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | unknown | Phase 2 | 23 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05823714 | Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT | unknown | Phase 2 | 70 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05749133 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | XuYanOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05809180 | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | unknown | N/A | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 9, 2023source: clinicaltrials